Is Bristol-Myers Squibb's Dividend Unbeatable?

Big pharma's home to many great dividends, but is Bristol-Myers Squibb's yield the best bet for your money?

May 20, 2014 at 7:12PM

There's a lot that goes into a great dividend stock, but it all starts out with a great dividend yield that you can trust to be there for the long term. Big pharma's an industry with a number of top dividend stocks, with cash flow aplenty and a history of dividend raises among some of the biggest names -- but with sales under pressure because of the patent cliff, this sector's fallen under scrutiny among long-term income investors. Bristol-Myers Squibb (NYSE:BMY) is one stock with a great dividend that's withstood the blow of patent expirations, but can this dividend make you rich in the long run?

The loss of former top-selling drug Plavix's patent protection has slammed Bristol's performance, but the company's looking to brighter days in the future. Bristol's gearing up its pipeline with new candidates to deliver strong sales for the long run, and no drug under this company's development looks stronger right now than potential cancer-fighting therapy nivolumab. Analysts have pegged nivolumab's peak sales at up to $4 billion or more, and despite shifting moods around Wall Street over this drug lately, it's still among Bristol's best shot at sustaining and growing its dividend for years to come.

Yet does Bristol have more than just nivolumab to keep dividend investors happy? Take a look at what's making Bristol's dividend go, and what can keep it rising far into the future, in the following video, as Motley Fool contributor Dan Carroll takes you through the ins and outs of this big pharma stock with plenty of appeal to income investors.

Don't miss these top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend-paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers